Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Let's review...
From - 09/20/2006 Pohl – Letter to Shareholders http://www.ptsc.com/news/press_releases/20060920.asp “As a general rule, our portfolio license fees - whether or not discounted as a result of negotiation strategy - are related to the relevant revenues generated for a licensee by products associated with the licensed technology, rather than the overall size and revenue of the company purchasing a license.” IMO… Pohl was telling us 2 things in this release. First, don’t set our revenue expectations too HIGH based on the size/notoriety of the company in any announced signing. Second, he was reiterating that some signings were strategic, i.e. Sony, as was also stated at the annual SHM. Sony crosses many industries, i.e. Personal Computing, Home Entertainment, Mobile Electronics, Digital Imaging, Gaming, Car Audio, GPS, etc. Maybe the Sony deal was the leverage that helped us license some of the existing companies, Nikon, Seiko, Pentax, Olympus, and Kenwood….and hopefully many more. So maybe we forfeit 20M now, to make 500M in future signings. If this is the case, I can live with it.
Share
New Message
Please login to post a reply